Xin Lang Cai Jing·2025-11-04 03:30Core Viewpoint - Spring Medical's stock experienced a slight decline of 0.42% on November 3, with a trading volume of 152 million yuan, indicating a stable market presence despite minor fluctuations [1] Financing Summary - On November 3, Spring Medical recorded a financing purchase amount of 16.73 million yuan, with a net financing purchase of 5.98 million yuan after repayments [1] - The total financing balance reached 46.31 million yuan, accounting for 0.56% of the circulating market value, which is above the 90th percentile level over the past year, indicating a high financing activity [1] - No shares were sold or repaid in the securities lending market on the same day, with the lending balance also at zero, reflecting a high level of inactivity in this area [1] Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants [2] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems, with exports to various regions including Asia, South America, Africa, Oceania, and Europe [2] - As of September 30, 2025, the company reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit of 192 million yuan, reflecting a significant increase of 213.21% compared to the previous year [2] Dividend and Shareholder Information - Since its A-share listing, Spring Medical has distributed a total of 359 million yuan in dividends, with 309 million yuan paid out over the last three years [3] - As of September 30, 2025, the company had 6,164 shareholders, an increase of 4.12% from the previous period, with an average of 46,906 circulating shares per shareholder, down by 3.95% [2][3] - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund, both of which are new entrants among the top ten circulating shareholders [3]